|
VOLUME 1, ISSUE 1 (.50 CME
credit hours)
Expired: 4/18/08
HIV Resistance in Context: A Historical Perspective Integrating
Highlights from 14th CROI to Support Current HIV Practice
By taking a look at some of the lessons we’ve learned over the past
years in the area of HIV resistance, this introductory issue of
ResistanceWATCH© News assists readers in better
understanding how to apply new and evolving resistance data (with
highlights from CROI 2007) into their clinical practice, thereby
improving patient outcome. Read
more…
VOLUME 1, ISSUE 2 (.50 CME credit
hours
Expired: 6/19/08
“Hold ‘em or Fold ‘em”? Addressing Challenges in the Treatment
of Multi-Drug Resistant HIV
In this second issue of
ResistanceWATCH© News,
we try to tackle the challenging topic of multi-drug resistant (MDR)
patients. Although antiretroviral therapy has drastically improved
the prognosis of HIV infected individuals, it has resulted in
selection of virus resistant to most or all of our
currently-available therapies in some patients. We will try to
highlight some of the key issues relevant to these patients, and
look ahead to new treatment options which may soon improve our
choices.
Read more…
VOLUME 1, ISSUE 3 (.50 CME credit hours);
Expired 8/20/2008
Agents
in Expanded Access: Key Data from the XVI HIV Drug
Resistance
Workshop
In
this third issue of ResistanceWATCH© News, we focus our
attention on antiretroviral agents available through expanded access
in three drug classes: integrase inhibitors, CCR5 inhibitors, and
the new nonnucleoside reverse transcriptase inhibitors (NNRTIs). As
clinical experience with these
pipeline drugs
has been relatively brief thus far, researchers still have much to
learn about the evolution of resistance to these agents. This issue
of ResistanceWATCH News© highlights key data
presented at the XVI HIV Drug Resistance Workshop held June 12-16,
2007, in Barbados.
Read more…
VOLUME 2, ISSUE 1 (.50 CME credit hours);
Expired 2/5/2009
Putting Developments in HIV Resistance Into Context – Where
We Were and Where We’re Going
Combining drug resistance information with patient history
is now well recognized as a valuable tool for guiding the
success of antiretroviral therapy, so much so that this
information is now a routine component of HIV management and
therapeutic decision-making. This issue of
ResistanceWATCH News© illustrates
just how far we have come in our understanding of HIV drug
resistance over the past 26 years by highlighting past and
current knowledge in the field, when
and how to best detect
drug resistance, and how to optimally use resistance
information to guide treatment.
Read more…
VOLUME 2, ISSUE 2 (.75 CME credit hours);
Expired 4/8/2009
Improving Patient-Provider Communication: Addressing the
Complex Issue of Discussing Resistance, Resistance Testing,
and Adherence With Patients
Communicating with patients about the basics of resistance
and the need for resistance testing is complex and daunting,
but such communications are important. This issue of
ResistanceWATCH News©
is designed to facilitate a more learned approach to dealing
with this challenge, illustrating both the need for
increased communication as well as strategies for your busy
practice.
Read more…
VOLUME 2, ISSUE
3 (.50 CME credit hours);
Expired: 6/17/09
Data in Context: Data Related to HIV Drug Resistance and
Management of Treatment-Experienced Patients from two 2008
Conferences (6th EU HIV Drug Resistance Workshop
and CROI)
In recent months the United States FDA has approved three
new antiretrovirals, maraviroc, raltegravir and etravirine,
for use in treatment-experienced HIV-positive patients who
require a change of therapy in order to suppress viral
replication.
This issue of ResistanceWATCH News©
is designed to provide physicians and other healthcare
providers with important information on best practices in
assessing drug resistance and the management of treatment
experienced patients with recent data from the 6th
HIV Drug Resistance Workshop and CROI 2008.
Read more…
VOLUME 2, ISSUE 4 (.25 CME credit hours);
Expired: 9/29/09
Catching Up with Data Related to HIV Resistance- Related Treatment
Failure and the New IAS Guidelines
Never
have HIV infected patients and their providers had such a wealth of
treatment options and diagnostic technologies to guide treatment.
Along with these important new tools has also come an increased
understanding of HIV resistance and its prevention and management.
Increasing treatment options should not result in our loss of
diligence regarding drug resistance. It is crucial we implement our
knowledge and understanding of drug resistance to minimize its
occurrence. This is true not only in the resource rich settings
where now six drug classes are available, but also in resource
limited settings where finally we are seeing increasing patient
access to antiretroviral drug classes and options. This issue of
ResistanceWATCH News will attempt to provide some insight into
resistance-related treatment failure to help empower clinicians and
patients in both resource rich, and resource limited settings.
Read more…
VOLUME 2, ISSUE
5;
Expired: 10/22/09
Preserving Options--Step One: Preventing Evolution of Drug
Resistance in Newly Infected Individuals
Transmitted drug resistance is a concern for patients and
clinicians as well as policy makers. Preventing new
infections with drug resistant HIV is a challenge not only
in Western countries where drugs have been available for
many years, but also in resource-limited settings where
treatment has started only recently. New diagnostic
technologies have been developed that can improve detection
of resistant virus. The impact of different drug classes as
well as patient monitoring strategies (a key issue in many
resource limited settings) on failure and resistance are
being studied and better defined. All these have relevance
to the transmission of drug resistant virus. In this issue
of ResistanceWATCH News we will attempt to address some of
the key issues regarding transmitted resistance and discuss
their clinical relevance.
Read more…
VOLUME 2, ISSUE 6; Expired: 11/18/09
Weighing the Options: New Insights on PI and NNRTI
Susceptibility Scoring
Recently, new drugs have entered the clinical realm
providing patients with exciting new options. Novel protease
inhibitors, NNRTIs and drugs with new mechanisms of action
are resulting in greatly improved outcomes in highly
treatment-experienced patients, as well as opportunities for
use in earlier lines of therapy. Along with improved drug
development has come improvement in interpreting drug
resistance. Refined methods have been developed and applied
to these drugs, allowing better prediction of their response
for a given resistance test result. In this issue of
ResistanceWATCH, we examine this world of refined and
improved drug resistance interpretation and its utility in
clinical practice.
Read more…
VOLUME 2, ISSUE 7; Expired: 12/3/09
Interpreting
HIV Drug Resistance: Concordance or Contradiction?
Interpretation of genotypic resistance assay results remains one of the true
wonders of HIV medicine. The ability to convert strings of genetic code in to
improved patient care is a great achievement of the last decade. This has been
the result of the combined efforts of clinicians, patients and scientists around
the globe. Perhaps none deserve more credit than Professor Robert Shafer,
Founder and Director of the Stanford HIV Drug Resistance database – freely
available to anyone with internet access. Many interpretation systems are
currently available, some free of charge on academic websites. How these systems
compare, and what this means to clinicians and patients, are the focus of our
current ResistanceWATCH issue.
Read more…
|
